Cargando…
Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) have failed to overcome the high therapy resistance of Metastatic Uveal Melanoma (MUM) in contrast to the dramatic benefits of immunotherapy seen in many other tumor entities. Considering the poor clinical outcome and survival rates of MUM, the urge...
Autores principales: | Blomen, Chiara L., Kött, Julian, Hartung, Tabea I., Torster, Leopold K., Gebhardt, Christoffer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699813/ https://www.ncbi.nlm.nih.gov/pubmed/34945010 http://dx.doi.org/10.3390/cancers13246390 |
Ejemplares similares
-
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015) -
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020) -
Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019) -
Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma
por: Waninger, Jessica J., et al.
Publicado: (2022) -
Combined treatment of uveal melanoma liver metastases
por: Brasiuniene, B, et al.
Publicado: (2011)